Indinavir 400 mg Capsules

Generic Indinavir and the Crixivan Distinction

The first purchasing decision is to confirm that the intended medicine is generic Indinavir 400 mg capsules, not the former Crixivan brand. Health Canada's Drug Product Database records Crixivan 400 mg capsules, DIN 02233195, as cancelled post-market. That record concerns the Canadian registration of the branded product; it does not mean that the active ingredient itself has been cancelled, nor does it establish the authorization status of the generic catalogue product.

We offer oral Indinavir capsules in a 400 mg strength. Although Crixivan contained Indinavir in the form of indinavir sulfate, a brand history or old prescription bearing the Crixivan name should not be used by itself to identify a current product. Confirm the active ingredient, capsule dosage form, strength, prescribed dose, and quantity with the prescriber or pharmacist before ordering.

Product Identity and Role in HIV Treatment

Indinavir is an HIV-1 protease inhibitor. The current product is a 400 mg oral capsule, not a tablet, liquid, extended-release product, or fixed-dose combination. It is used with other antiretroviral medicines as part of combination treatment and should not be taken as stand-alone HIV therapy.

Protease inhibitors belong to one part of the wider range of HIV medicines. Indinavir differs from many newer options because a commonly used unboosted regimen requires doses every eight hours, food-timing precautions, and consistent fluid intake. Some regimens use protease inhibitors with a pharmacokinetic booster, which can change dose and administration instructions. The prescribed regimen, rather than the capsule strength alone, determines how Indinavir should be taken.

Modern treatment choices often favour newer combinations with simpler schedules, but that does not make every newer medicine suitable for every person. Previous treatment, resistance results, interactions, tolerability, and the other medicines in the regimen can all affect whether a clinician considers continuing or using Indinavir.

Who Might Discuss Indinavir With Their HIV Care Team?

Indinavir capsules have an established adult indication for HIV-1 infection when used with other antiretrovirals. A clinician may discuss them in the context of an existing effective regimen, previous treatment history, resistance findings, or a need to assess alternatives. The medicine should not be selected solely because a particular package is available.

Important decision factors include:

• Schedule: whether the prescribed timing can be followed consistently, including overnight or workday doses if an every-eight-hour regimen is used.
• Kidney and urinary history: Indinavir is associated with kidney stones, making hydration and monitoring particularly important.
• Pregnancy: Indinavir is not recommended as a component of an antiretroviral regimen during pregnancy because drug exposure can fall substantially.
• Breastfeeding: product guidance advises against breastfeeding while taking Indinavir.
• Blood glucose: new or worsening diabetes and high blood sugar have been reported with HIV protease inhibitors, including Indinavir.
• Age: safety and effectiveness have not been established for patients under 18 years, and there is no approved pediatric dose for this product.
• Other medicines: Indinavir has clinically important interactions that can make some combinations unsuitable or require specialist adjustment.

These points guide a discussion rather than determine treatment on their own. A prescriber who can review the complete HIV regimen and medical history is best placed to decide whether Indinavir remains appropriate.

How Does Indinavir Work, and What Does That Mean in Practice?

HIV produces long chains of viral proteins that must be cut into functional parts before new virus particles can mature. Indinavir blocks HIV protease, the enzyme responsible for that processing step. The resulting viral particles are immature and less able to infect additional cells. Because Indinavir acts at one stage of the viral life cycle, it is combined with antiretrovirals that act through other mechanisms.

The practical consequence is that regular dosing matters. Irregular doses can produce drug levels that are too low to suppress viral replication reliably, increasing the risk of treatment failure and resistance. The medicine does not provide a sensation that confirms it is working. Viral load, CD4 count, laboratory findings, adverse effects, and adherence are assessed by the treating team over time.

Food and interacting medicines can alter Indinavir exposure. Administration instructions are therefore part of the treatment plan, not optional suggestions. Do not change the timing, combine doses, or alter the regimen to make it more convenient without first obtaining clinical advice.

Building a Safe and Practical Routine

The usual unboosted adult regimen cited in product information is 800 mg every eight hours, which equals two 400 mg capsules per dose. This is general information, not an individual dosing instruction. A prescriber may provide different directions because of another antiretroviral, an interacting medicine, liver function, or the structure of the complete regimen.

A practical routine should address all of the following:

1. Follow the prescription exactly. Use the number of 400 mg capsules and dosing interval stated for the complete regimen.
2. Observe the food instructions. Unboosted Indinavir is generally taken without food, usually one hour before or two hours after a meal, or with a light, low-fat meal when permitted by the prescriber. Instructions can differ when the regimen includes a booster.
3. Space doses consistently. For an every-eight-hour prescription, choose times that can realistically be maintained every day rather than clustering doses during waking hours.
4. Maintain the advised fluid intake. Product guidance recommends at least 1.5 L of fluid over 24 hours to help reduce the risk of kidney stones. Anyone who has been told to restrict fluids should ask the treating clinician for individualized advice.
5. Swallow the capsules as directed. Do not open, crush, or otherwise alter them unless a pharmacist specifically confirms that this is appropriate.
6. Plan for missed doses in advance. Obtain instructions from the HIV care team or pharmacist; do not take an extra dose unless specifically directed.

Store the capsules at 15°C to 30°C in their original tightly closed container. Keep the desiccant, or drying agent, in the container to protect the capsules from moisture. Do not transfer a long-term supply to a container that cannot provide equivalent moisture protection.

Available Strength and Package Quantities

Our catalogue includes Indinavir oral capsules in one strength, 400 mg, with package quantities of 30 or 60 capsules. These are quantity choices for the same strength and dosage form; they are not different doses or release types.

If the prescribed regimen is the usual unboosted dose of 800 mg every eight hours, six 400 mg capsules are taken per day. At that specific prescribed rate, 30 capsules represent five days and 60 capsules represent ten days. A different prescribed regimen changes how long either package lasts, so calculate the required quantity from the actual directions rather than from the capsule strength alone.

Indinavir is one component of combination therapy. Before choosing a quantity, compare its refill timing with the other antiretrovirals in the regimen and confirm that the prescription covers the intended supply. Do not extend a supply by skipping doses or taking fewer capsules than prescribed.

What Outcomes and Timing Can You Expect?

An Indinavir-containing regimen is intended to suppress HIV replication over the long term. It is not a short course and does not eradicate HIV. Treatment response is evaluated with viral-load testing, CD4 counts, clinical review, and other laboratory monitoring selected by the treating clinician. The timing and frequency of those tests depend on treatment history and the complete regimen, so a fixed result date should not be inferred from the package size.

Some adverse effects may appear before any laboratory measure of benefit is discussed. Nausea, abdominal discomfort, headache, dizziness, or changes related to elevated bilirubin can occur. Elevated bilirubin may cause yellowing of the skin or eyes. New yellowing, severe or persistent symptoms, reduced urine output, painful urination, blood in the urine, or pain in the side or back should be reported promptly because they can require assessment.

Feeling well does not show that the virus is fully suppressed, and feeling unwell does not necessarily mean the regimen has failed. Continue the medicine as directed while seeking advice unless urgent medical care or a clinician's instructions require otherwise.

Safety Priorities Before and During Treatment

Indinavir has several safety considerations that directly affect whether the medicine is a practical choice:

• Kidney stones and urinary complications: nephrolithiasis is a recognized risk. Hydration helps reduce risk but does not eliminate it. Flank pain, blood in the urine, painful urination, or difficulty passing urine needs prompt medical attention.
• High bilirubin: Indinavir can increase bilirubin and cause yellowing of the skin or eyes. A clinician may need to distinguish this medicine-related effect from liver or gallbladder disease.
• Blood sugar changes: new diabetes, worsening existing diabetes, and high blood sugar have been reported with protease inhibitors. Increased thirst, frequent urination, or unexplained changes in glucose control should be discussed with a clinician.
• Pregnancy: Indinavir is not recommended during pregnancy because maternal drug exposure can be substantially reduced, potentially producing inadequate antiretroviral concentrations. Pregnancy planning should be discussed before changing treatment.
• Breastfeeding: the product guidance advises against breastfeeding during treatment. Feeding decisions should be discussed with the HIV care team.
• Driving and machinery: dizziness or blurred vision can impair these activities. Avoid driving or operating machinery if affected.
• Allergy: known clinically significant hypersensitivity to Indinavir or a capsule component is a reason not to use the product.

Safety and effectiveness have not been established in patients under 18 years, and limited pediatric data do not provide an approved dosing approach for these capsules. Indinavir should therefore not be presented as a routine pediatric option.

Interactions and Precautions That Can Change the Regimen

Indinavir is affected by CYP3A4, an enzyme involved in the metabolism of many medicines. Some products can lower Indinavir concentrations and undermine viral suppression, while others can raise concentrations of Indinavir or the interacting medicine and increase toxicity. The importance of these interactions means a complete medication review is needed before treatment and whenever another product is started or stopped.

Rifampin and St. John's wort can substantially reduce Indinavir exposure and should not be combined with it. Certain anticonvulsants and other strong enzyme inducers may have a similar effect. Some sedatives, heart medicines, cholesterol-lowering medicines, erectile-dysfunction treatments, and other products metabolized through CYP3A4 can also create serious interactions. This is not a complete interaction list.

Other antiretrovirals can change the dose or monitoring plan. For example, Nevirapine can reduce Indinavir concentrations, while ritonavir can increase them and is sometimes used as a booster. Such combinations require prescriber-directed dosing; they should not be created or adjusted independently.

Provide the pharmacist and prescriber with a list of prescription medicines, non-prescription products, vitamins, supplements, and herbal remedies. Also discuss liver disease, kidney or urinary problems, diabetes, hemophilia, pregnancy, and any previous reaction to an HIV medicine.

Conditional Comparison With Other Regimen Options

Indinavir is not universally better or worse than another protease inhibitor. The useful comparison is whether its schedule, interaction profile, previous treatment response, and specific adverse-effect risks fit the regimen being considered.

Newer boosted protease inhibitors such as darunavir or atazanavir are often used once or twice daily, depending on the regimen. That may be easier than an unboosted every-eight-hour Indinavir schedule, but boosting introduces its own interaction considerations, and each medicine has a distinct safety profile. Older options such as saquinavir and nelfinavir may also involve substantial dosing or tolerability burdens. Tipranavir and fosamprenavir may be considered in particular treatment histories, including situations shaped by resistance results, rather than simply as more convenient substitutes.

Kaletra combines lopinavir with ritonavir in one product. Its built-in booster and dosing schedule differ from those of unboosted Indinavir, but suitability still depends on resistance, interactions, tolerability, and the other components of therapy.

A second comparison concerns the entire regimen rather than the protease inhibitor alone. Nucleoside reverse-transcriptase inhibitors may form the treatment backbone; for example, Combivir combines lamivudine and zidovudine. It is not a direct substitute for Indinavir, and the two products occupy different roles. A clinician may compare one complete combination regimen with another after reviewing viral resistance, previous adverse effects, and current treatment goals.

Canadian Prescription and Coverage Context

Indinavir and its salts are prescription drugs in Canada. Treatment should be authorized and managed by a qualified prescriber, regardless of which pharmacy supplies the medicine. This regulatory classification is separate from an individual pharmacy's order-processing procedures.

Health Canada's post-market cancellation record for Crixivan does not establish the authorization status of the generic catalogue product. Customers should therefore avoid treating the old brand's DIN or packaging as proof that another product is identical in manufacturer, regulatory status, or supply chain.

Canada has no single nationwide public formulary that determines antiretroviral coverage for every resident. Eligibility and reimbursement can differ among provincial or territorial programs and private insurance plans. Coverage should be confirmed directly with the applicable plan; a listed catalogue price does not determine reimbursement.

Suspected adverse reactions can be reported to Health Canada through the Canada Vigilance Program. This federal reporting service is separate from contacting the treating clinician, pharmacist, or our support team about an immediate concern.

Ordering and Delivery Preparation

Before placing an order, confirm that the prescription or treatment instructions specify Indinavir oral capsules, the 400 mg strength, the number of capsules per dose, the dosing interval, and the required quantity. Brand history alone is not enough to identify the intended product. We offer package quantities of 30 and 60 capsules, and our prices are presented in Canadian dollars.

Our site has operated since 2010. Customer support is available 24/7 by email, online chat, and phone, and pharmacist support is also available for product and medication questions. A pharmacist can help clarify the dosage form, strength, storage requirements, or questions that should be referred to the prescriber, but cannot independently replace the prescribed HIV regimen.

When preparing an order for delivery in Canada, verify the recipient details, street address, and postal code carefully. Keep the expected refill date in mind because even the 60-capsule package represents a limited number of days when six capsules are prescribed daily. Delivery timing should be considered before the existing supply runs low, and doses should not be stretched if another supply has not yet arrived.

A Focused Decision Summary

Indinavir 400 mg capsules may be relevant when a clinician has selected or continued an Indinavir-containing combination regimen. The key distinction is not merely that Indinavir belongs to the protease-inhibitor class. Its commonly used unboosted schedule, food timing, hydration requirement, kidney-stone risk, interaction profile, and limited package duration all affect whether it is practical.

Before ordering, confirm five points: the exact capsule product and 400 mg strength, the prescribed number of capsules per dose, the timing and food instructions, the quantity needed until the next refill, and the compatibility of every other medicine or supplement. If those details match the treatment plan, select the prescribed package quantity and retain the capsules in their original tightly closed container with the desiccant. Questions about suitability, dose changes, pregnancy, adverse effects, or interactions belong with the prescriber or pharmacist rather than being resolved through product comparison alone.